Enamine, Lundbeck extend multi-year CNS drug discovery deal

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Olique)
(Image: Getty/Olique)
Lundbeck extends its research collaboration with the drug discovery services provider Enamine to help “intensify its search for quality lead compounds.”

Lundbeck is a global pharmaceutical company developing drugs for the treatment of central nervous system (CNS) disorders.

The company this week announced that it has expanded its research collaboration with Enamine, as part of which the service provider will support Lundbeck’s in-house discovery chemistry competencies.

For more than 12 years, Lundbeck has been using Enamine's library of screening compounds to support its work. According to the company, Enamine has the world's largest collection of screening compounds, at more than 2.6m, in addition to 170k building blocks.

As part of its work with Enamine, Michael Bossert, head of strategic alliances at Enamine said, “Lundbeck realized the scope of working with Enamine was potentially much greater and they had expertise to deploy a huge chemical space giving access to billions of compounds.”

A more formal collaboration was established in 2017, which gave Lundbeck access to “billions of virtual compounds that could be synthesized within only 3 weeks and with over 80% success rate,"​ Bossert told us.

“This speed and success rate with the further benefit of having 170,000 building blocks, was the basis of this latest phase in the companies' collaboration involving dedicated full-time chemists,”​ he added.

“The announced extension step will help Lundbeck further intensify its search for quality lead compounds that can be used in its research programs.”

Related news

Show more

Related products

show more

Powered by Ingredients + Innovation

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA | 07-Oct-2024 | Product Brochure

In partnership with our industry-leading supplier partners, Univar Solutions Pharmaceutical Ingredients is proud to introduce Powering Healthy Tomorrows.

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us

Products

View more

Webinars